Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.
08:03am, Tuesday, 24'th Mar 2026
Gilead plans to develop Ouro's lead drug candidate, gamgertamig, alongside a Belgian pharma company.
Breakfast News: Gilead Bets Big on Its Next Phase
07:30am, Tuesday, 24'th Mar 2026
Gilead makes $2 billion purchase, Tesla enjoys European sales growth, and more
Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion
06:55pm, Monday, 23'rd Mar 2026
Gilead said the deal would bolster its growing inflammation portfolio.
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal
06:28pm, Monday, 23'rd Mar 2026
Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines in a deal worth up to $2.18 billion.
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
06:15pm, Monday, 23'rd Mar 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology
Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports
12:44pm, Monday, 23'rd Mar 2026
Gilead Sciences is nearing an acquisition of biotech firm Ouro Medicines for up to $2 billion, the Financial Times reported on Monday, citing people familiar wit
Confluence Investment Management LLC Trims Stock Position in Gilead Sciences, Inc. $GILD
06:06am, Friday, 20'th Mar 2026
Confluence Investment Management LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 4.5% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned
5 Stocks to Buy in a High-Risk Bull Market
02:15pm, Thursday, 19'th Mar 2026
From Big Tech to overlooked value plays, Victoria Fernandez shares 5 stocks to own in a “high-risk bull market”—and where she sees opportunity despite rising risks.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
10:01am, Thursday, 19'th Mar 2026
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
07:00pm, Wednesday, 18'th Mar 2026
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $141.29, denoting a -2.15% move from the preceding trading day.
TrumpRx lists many medicines at prices higher than paid in UK
02:23pm, Wednesday, 18'th Mar 2026
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those
Gilead Sciences, Inc. $GILD Shares Purchased by Achmea Investment Management B.V.
03:22am, Wednesday, 18'th Mar 2026
Achmea Investment Management B.V. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 5.4% in the third quarter, according to the company in its most recent filing with the Securi
Bank of Nova Scotia Sells 319,843 Shares of Gilead Sciences, Inc. $GILD
04:14am, Tuesday, 17'th Mar 2026
Bank of Nova Scotia reduced its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 55.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Comm
Bamco Inc. NY Purchases 5,500 Shares of Gilead Sciences, Inc. $GILD
03:36am, Tuesday, 17'th Mar 2026
Bamco Inc. NY lifted its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 29.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commissi
Alliancebernstein L.P. Sells 258,213 Shares of Gilead Sciences, Inc. $GILD
06:10am, Sunday, 15'th Mar 2026
Alliancebernstein L.P. cut its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 4.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commissio
